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Natural killer (NK) cells constitute an imporltant component of the innate immune system and as such form part of the body’s first line 
of defense against diseases, such as cancer.1 NK cells 
originate from hematopoietic stem cell progenitors in 
the bone marrow and are characterized in humans as 
CD56lpositive CD3lnegative lymphocytes.2 NK cells 
are capable of a spontaneous MHClunrestricted cyl
totoxic antiltumor response (‘natural cytotoxicity’), 
mediated and fineltuned through an array of activating 
and inhibitory NK cell receptors. Direct interactions 
between NK cell activating receptors and tumor cell lil
gands enable fast cytotoxic responses to a broad range 
of malignancies.3,4 Engagement of NK cell inhibitory 
receptors, on the other hand, is an important measure 
in preventing cytotoxicity against self. Importantly, NK 
cells, different from T cells, do not induce graftlversusl
host disease (GVHD) in patients after clinical allogel
neic transplantation.5l9 These features render NK cells 
highly promising candidates for clinical applications 
to combat cancer through adoptive immunotherapy 
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natural killer (nK) cell therapies are emerging worldwide as promising anticancer treatments, exploiting 
the fast cytolytic action of nK effectors and their potentially broad applicability against a wide range of 
malignancies. until recently, clinical protocols have mainly involved freshly isolated nK cells or short-
term activated nK cells or lymphokine-activated killer (laK) cells. however, overall effector numbers and 
their anticancer potencies remained restricted, which poses a limiting factor to clinical efficacy. recent 
developments in the field aim to improve clinical trial designs by increasing effector to target cell ratios 
in vivo and by application of superior cytotoxic nK effectors. large-scale production of clinical grade nK 
cells through long-term activation in ex vivo cultures are another novel means in achieving these goals. 
however, such procedures require compliance with the strict Good manufacturing practice (Gmp) regula-
tions to ensure quality and safety of the nK cell product. although the overall number of new protocols 
still remains comparably low, some of the protocols are already translated into clinical use. also striking is 
the diversity of the different protocols proposed. We highlight in this review the most recent developments 
in the nK cell field with a focus on long-term nK cell expansion. critical issues relating to this novel and 
promising type of therapy are highlighted and discussed.
(AIT).10,11 Cellular therapies are worldwide relemergl
ing as promising modalities in modern medicine.12l15 
This renewed interest is triggered at least in part by 
recent advances in cell selection technologies, cell actil
vation modes, and novel cell culture strategies, allowl
ing more effective manipulations of blood and marrow 
derived products. This review focuses on novel promisl
ing directions in the clinical NK cell field, which involve 
Good Manufacturing Practices (GMP)lcompliant 
largelscale NK effector production through longlterm 
ex vivo activation and expansion.
Traditional immunotherapies against cancer 
involving NK cells
The cytokine interleukin (IL)l2 was the first lymphol
cytotrophic interleukin molecule discovered16,17 and 
is generally employed to stimulate and expand NK 
cells.18l20 The cytokine’s potential to significantly acl
tivate NK cell cytotoxicity,21 also enabling them to 
overcome resistance posed by certain tumor cells to unl
stimulated NK cells has been well established.22,23 The 
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earliest clinical immunotherapy approaches, developed 
by Steven A. Rosenberg and colleagues at the National 
Cancer Institute in the USA, involved highldose sysl
temic ILl2 infusions exploiting the immunostimulatory 
functions of the cytokine for endogenous NK cell acl
tivation.24 Furthermore, shortlterm (3l5 days) ex vivo 
ILl2 stimulated autologous lymphokine activated killer 
(LAK) cells were clinically applied in AIT.24 However, 
neither approach was particularly clinically effective.25l
27 Main obstacles included the low effector number 
in such shortlterm ILl2 stimulated LAK cell populal
tions (only about 10%l20%) and their moderate cytol
toxic potential. Furthermore, systemic application of 
highldose ILl2 to stimulate endogenous NK cells in 
vivo caused severe toxicities (cytokine storm).25 Most 
susceptible to such treatments were renal cancer28 and 
metastatic melanoma.29l31 Low dose ILl2 injections, 
on the other hand, although nonltoxic, biased expanl
sion of NK cells, which lacked cytotoxic potential.32l34 
Intermediate bolus (pulse) therapy involving higher 
doses of ILl2 was necessary to generate effectors with 
measurable cytotoxicity. As such, neither highl nor lowl
dose ILl2 monoltherapies seem to hold great promise 
for NK cell therapy. This was similarly stated in a rel
cent study comparing administration of overnight (o/
n) ILl2 activated NK (LAK) cells with ILl2 boluses 
at tolerable doses postltransplant to patients suffering 
from lymphoma and breast cancer. No improvements 
in disease outcomes were noted.35 Combination theral
pies of lowldose ILl2 with additional NK cell growth 
factors, such as clkit ligand, flt3 ligand or IFNlβ, have 
been suggested and may provide other options for in 
vivo stimulation of NK cell differentiation in the ful
ture.31,34,36 Furthermore, novel cytokines, such as ILl15, 
with important functions in NK cell activation, survival 
and homeostasis, are currently clinically developed.37
Encouragingly, clinical trial studies conducted over 
the past few years in the allogeneic transplant setting 
for targeting hematological malignancies have deml
onstrated definite antilleukemia6,7,38 and antiltumor7 
effects of NK alloreactivity. In these clinical trials, a 
mismatch between donor’s NK inhibitory killerliml
munoglobulinllike receptors (iKIR) and their cogl
nate MHC class Illigands in recipients (KIRlligand 
mismatch) eliminated the otherwise inhibitory KIRl
ligand interactions.39 However, the clinical benefit of 
reduced relapse rate was most consistently observed 
in haploidentical or cord blood transplants, whereas 
in other transplant scenarios, e.g. involving unrelated 
donors, contradictory therapy outcomes were reportl
ed for NK alloreactivity.27 Despite recent progress in 
the field, experience in this novel area is still compal
rably limited. Although alloreactive hematopoietic cell 
transplants could provide potential cure for a range 
of hematological malignancies in adults and pediatric 
patients, severe infections and related toxicities occurl
ring in patients after treatment with intensive hapl
loidentical conditioning regimens pose limitations to 
its routine applicability.40 A novel and more tolerable 
approach involving patients in disease remission post 
chemotherapy has been recently proposed and tested in 
a promising pilot study.7,41 Haploidentical, KIRlligand 
mismatched purified NK cell infusions (NKAML) afl
ter low dose immunosuppression (Cyclophosphamide 
and Fludarabine) allowed transient NK cell engraftl
ment to exert alloreactivity.41 However, future investil
gations are needed to further explore the potential of 
such novel approaches of allogeneic NK cell therapy in 
a nonltransplant setting.42
In general, NK cell numbers in fresh, unstimulated 
grafts or in shortlterm ILl2 stimulated NK cell prodl
ucts are low and cytotoxicity of such effectors moderl
ate.20,27 Longlterm NK cell ex vivo expansion in clean 
roomllaboratories under conditions, which are coml
pliant with rigorous GMPlstandards.43l45 is a valuable 
novel option to allow largelscale production of highly 
potent NK effectors.20 This approach enables clinical 
administration of greater NK cell numbers with the aim 
to tilt the effector to target ratio for more efficient antil
tumor effects. In addition, a larger lotlproduction may 
enable longer term cryostorage of product batches and 
permit multiple applications from a given batch to the 
patient. Furthermore, NK cell functions may also be iml
paired in diseased patients and shortlterm stimulation 
would be insufficient to recover them to high functionl
ality.20 However, powerful protocols to support NK cell 
growth and activation in culture are pertinent to this 
type of NK cell therapy. Another successful example for 
longlterm culture of antilcancer effectors is production 
of cytokinelinduced killer cells, which have been applied 
in clinical trials since 1999.46
Novel approaches for generation of highly pot
tent clinical grade NK cells in longtterm cultures
Several protocols for in vitro NK cell expansion have 
been previously established in research laboratories.19,47 
Generally, a significant boost in NK cell expansion 
and activity over simple ILl2 cytokine stimulation was 
achieved through NK cell colculture with (irradiated) 
feeder cells, such as autologous or allogeneic (activatl
ed) peripheral blood mononuclear cells (PBMCs) or 
EpsteinlBarrlVirus (EBV)ltransformed lymphoblastoid 
cell lines (LCLs;.47l51 Recently, however, the emergence 
of GMP standards compliance has restricted wide applil
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cability of many of these protocols and to date43l45 only a 
small number have been clinically translated.20,52l54
Novel GMP-compatible protocols-general       
remarks
In this section we discuss some of the most recently prol
posed protocols for largelscale NK cell production, some 
of which have found their way into clinical applications.52l
55 For further details on previously published protocols, 
which may not be mentioned in detail here, we refer to 
other recent reviews.20,56 In general, current protocols 
which have been developed for generation of clinical grade 
NK effectors vary greatly in their design.20,53,56 When anal
lyzing and comparing results achieved with such differing 
methods, close attention needs to be paid to a number of 
parameters. Critical factors include the efficiency of the 
protocol in supporting NK cell activation and growth, 
presence of feeder cells and their characteristics, additions 
of animallderived reagents and grading (GMPl or clinil
callgrade) of culture components, such as culture media, 
growth factors and serum components. Relevant too are 
the cell density that can be reached in cultures, which afl
fects culture size and amounts of medium required, the 
frequency of media addition or media exchange, and the 
type of culture containment, e.g. the type of culture bags 
employed (pore size for example). Furthermore, involvel
ment of cell sorting or cell enrichment procedures, are 
equally important parameters to note.
Effector generation in an AIM V based formula 
for multiple myeloma patients
A GMPlcompliant method has been developed for 
generation of highly activated autologous effector cells 
for the treatment of multiple myeloma patients after 
highldose chemotherapy and autologous peripheral 
blood stem cell transplantation.55 The protocol is based 
on the traditional serumlfree lymphocyte medium 
AIM V, supplemented with high dose ILl2 (1000 IU/
mL) and Orthoclone OKTl3 throughout culture dul
ration. Effector lymphocytes were expanded from the 
nonladherent fractions of chemotherapylmobilized pel
ripheral blood haematopoietic progenitor cells (HPC) 
from myeloma patients. The expanded cell product 
comprised a polyclonal population of cytotoxic lyml
phocytes, which could mediate cytotoxicity through 
different mechanisms and potentially overcome tumor 
escape mechanisms.55 Cells were expanded for 7 days, 
followed by cryopreservation. The authors observed no 
difference for the phenotype of the cells between cull
tures in flasks compared to GMPlculture bags and only 
a slight increase in cytotoxic potential against K562, 
but not against the myeloma cell line RPMI8226 for 
cells grown in bags. The optimal cell concentration 
for expansion in culture bags was determined as 2.5l
3.5×106 cells/mL. Importantly, cryopreservation did 
not alter the cell’s phenotype or NK subset composition 
and furthermore did not negatively affect viability and 
cytotoxicity of the product. A cryopreservation step bel
fore product administration to patients would therefore 
be feasible and allow time for obtaining release testing 
results (sterility, mycoplasma e.g.). 
However, expansion of the peripheral blood HPCs in 
this protocol remained overall very low at about 2l3lfold 
only. Perhaps culture for extended time periods would 
result in increased expansion, since a lag time of 5l7 days 
for NK cell proliferation in culture had been previously 
observed.57 However, the authors found that the majority 
of multiple myeloma patients could mobilize sufficient 
starting cells for feasible infusion of the product. The 
protocol has been translated into a clinical trial.55
A CellGro SCGM based method generates large-
scale NK cell products
Another similar protocol based on the serumlfree mel
dium CellGro SCGM achieved exceptional expansion 
results, several hundred to several thousandlfold, for 
NK cells within LAK populations.58 Culture duration 
was 3 weeks and cells could be expanded from healthy 
donor PBMCs and samples from patients with either 
multiple myeloma (MM)59 or Blchronic lymphocytic 
leukemia (BlCLL).60 CellGro SCGM was supplementl
ed with 5% human serum, ILl2 (500 IU/mL), and the 
recombinant antilhuman CD3 antibody (Orthoclone 
OKT3; 10 ng/mL added for the first 5 days). The prol
tocol is straight forward and does not include an adhel
sion step. However, cell concentration was comparably 
low in such cultures with 5×105 cells/mL (to avoid conl
tact inhibition), which would require larger culture voll
umes and media amounts for processing. The authors 
had termed the product, which comprised on average 
55% NK cells ‘cytokinelinduced natural killer (CINK) 
cells. Other culture media, the serumlfree media AIM 
V and XlVIVO 15, and the basic medium RPMI 1640, 
did not support the expansion of the NK cell subset in 
this protocol.58 Importantly, CellGro SCGM expanded 
LAKlNK cells showed cytotoxicity against autologous 
MM samples and were nonltoxic against healthy cells.
Expansion of NK cells within LAK populations 
could be more efficient compared to expansion of highly 
purified NK cells due to the production of cytokines 
and other factors in the LAK population supporting 
NK cell activation and growth.57 This approach is valul
able and costleffective for the autologous transplant setl
ting. However contaminating T cells could pose a risk 
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of GVHD in the allogeneic settings.57 Nevertheless, the 
protocol has been tested in a small clinical study with 
cancer patients and was found safe for allogeneic LAK 
cell infusions following allogeneic HSC transplantation 
involving the same donor.52 CD3ldepletion with magl
netic beads at culture end could be an option for other 
allogeneic settings.
Genetically modified K562, K562-mb15-41BBL, 
for clinical grade NK cell production
CellGro SCGM has also been used to support growth of 
purified NK cells or NK cells within LAK cultures inl
volving lethally irradiated genetically modified K562 exl
pressing NK stimulatory 4l1BB ligand and ILl15 (K562l
mb15l41BBL) for activation.54,61 A master cell bank of 
K562lmb15l41BBL was developed following GMPl
guidelines.54 The method was termed NK Cell Activation 
and Expansion System (NKAES) by the authors54 and 
was recently reviewed.56 There was efficient antileukemic 
capacity of NKAESlNK cells demonstrated in vitro and 
in a murine model xenografted with AML.54 However, the 
in vivo data also revealed that multiple effector injections 
were necessary to achieve eradication of leukemia and 
longlterm remissions. These results provide strong evil
dence for a beneficial effect of repeated NK cell adminisl
trations in clinical cancer treatment. It further emphasizes 
the benefit of largelscale NK cell generation for batch prol
duction. NKAESlNK cells are also candidates for solid 
tumors targeting, since their cytotoxicity against derived 
cell lines, including Ewing sarcoma (EWS) and rhabdol
myosarcoma could also be demonstrated.62 The method 
is currently tested clinically against leukemias and solid 
tumors.54,56,62 Another GMPlcompliant variation of this 
method for clinical application was proposed for tumorl
specific targeting of K562lmb15l41BBLlstimulated NK 
cells. Cells were transfected by electroporation (MaxCyte, 
Gaithersburg, MD) at days 6l12 with mRNA encoding 
an antilCD19 chimeric antigen receptor (antilCD19lBBl
z) for targeting Blcell lymphomas.63 The method has been 
discussed by the authors as simple, safe and cost effective63 
and offers a means for overcoming tumor cell resistances 
as known for BlALL.56,64
Single-KIR positive NK effectors to mediate spe-
cific alloreactivity
Another protocol involving CellGro SCGM has been 
developed for clinical translation, which allows largel
scale expansion of singlelKIR positive NK cells expressl
ing high levels of activating receptors.65 This method 
enables a refined study design for NK cell alloreactivl
ity for treatment of leukemia by excluding ‘background 
noise’ in the bulk LAK or NK cell product. Culture voll
umes required for processing are significantly reduced. 
Importantly, this method allows valuable direct investil
gation of cytolytic effects of alloreactive NK cells with 
relevance for commonly practiced predicted KIRlHLA 
mismatches.65 Potency of HLAlmismatched singlelKIR 
NK cells was demonstrated in vitro against AML blasts 
and in vivo in an AML xenografted mouse model usl
ing repeated cell infusions. Notably, addition of ILl15 to 
the ILl2lbased culture protocol significantly prolonged 
survival of the effectors in vivo. However, such a protol
col consequently involves a higher degree of complexity. 
The procedure starts with a 2lstep magnetic NK cell 
isolation (CD3+l depletion and CD56+lselection) usl
ing the CliniMACS system (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Purified NK cells are then further 
sorted into singlelKIR NK cells using the highlspeed 
BD Biosciences Influx Cell Sorter for GMPlcompatible 
purification. Purity and viability of the sorted cells were 
high, with 98.6% and 84.5%, respectively. Single KIR 
NK cells were expanded for 19 days in a variation of the 
previously published CellGro protocol.58 The magnetil
cally NK cell depleted cell fraction from the CliniMACS 
procedure was used as autologous feeder cells after irl
radiation and ILl15 was added to supplement ILl2 as 
additional cytokine. The contaminating T cell fraction 
remained minimal with 0.002l0.010% after expansion. 
The authors found that the overall T cell content was 
reduced in cultures containing additional ILl15, which 
also enhanced cell growth in largelscale cultures. Under 
the above conditions, single KIR NK cells expanded 
159.8l to 390.1lfold in GMPlculture bags (Baxter 
LifeCell) within 19 days. Alloreactive singlelKIR exl
ceeded cytolytic potential of bulk alloreactive NK cells 
against AML blasts in accordance with the hypothesis of 
alloreactivity. The output of this protocol as discussed by 
the authors would allow a single high cell number inful
sion or repeated low cell number infusions. However, it 
was noted that GMPlgrade or clinical grade monoclonal 
antilKIR antibodies are currently unavailable. The pal
per also discussed a potential pharmacologic treatment 
in addition to the NK cell administration. Useful drugs 
could include histone deacetylase (HDAC) inhibitors 
trichostatin A or valproic acid for sensitizing AML 
blasts to NK cell lysis, targeting selflrenewing leukemic 
blasts, and for prevention of relapse.65,66
EBV-TM-LCL stimulated clinical grade NK cells 
in combination with bortezomib for advanced 
malignancies
This is an interesting protocol being translated into 
a clinical trial for the treatment of patients with adl
vanced malignancies (including solid tumors, leukel
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mia, and melanoma.53 Besides largelscale production 
of potent NK effectors, it involves the novel use of the 
proteosome inhibitor bortezomib (Velcade, PSl341, 
Millenium Pharmaceuticals) to sensitize tumor cells 
to NK cell killing. Bortezomib was first approved in 
2003 for clinical application against multiple myeloma 
(MM). Its potential wider application against other 
cancer types is currently also explored.67l70 Importantly, 
bortezomib preltreatment of tumor targets could senl
sitize them to NK cell cytolysis mediated through difl
ferent mechanisms, including HLA class I downregul
lation on targets or increase in surface expression of 
DR5 (tumor necrosis factorlrelated apoptosis inducing 
ligand (TRAIL)lR2.67,71l73 In fact, promising studies in 
mice showed that a combination of NK therapy with 
bortezomib significantly increased survival.72 However, 
an inhibitory effect of bortezomib on cytotoxicity of 
resting or shortlterm ILl2 activated NK cells was also 
found.74,75 Although lowldose bortezomib may not 
impair NK cell function,71 sequential rather than sil
multaneous application of the drug and immunotheral
peutic NK cells has been suggested for a combination 
approach in immunotherapy.67
Berg et al53 aimed to overcome inhibitory KIR 
receptor inhibition and enable potent antilcancer efl
fectiveness of autologous NK cells with their new 
Table 1. Changes in surface receptor expression after long-term activation of NK effectors. Highlights show receptors, for which 
expression changes were detected in more than one protocol.
Culture 
day Upregulated receptors
Downregulated 
receptors Unchanged receptors Feeder cells Citation
12
Activating
CD56, NKG2D, CD48, 
LFA-1, NKG2C, CD244 
(2B4)
Inhibitory
NKG2A (MFI), KIR3DL1 
(MFI)
EBV-LCL (irradiated; 
master cell bank 
derived)
53
Inhibitory
NKG2A (%) KIR2DL2, 
KIR2DL3, KIR3DL1 (%)
Others
FasL, TRAIL CD25 
(IL2Rα)
7
Activating
NKG2D, NKp30, NKp44, 
NKp46
K562-mb15-41BBL 
(irradiated; master cell 
bank derived)
54Others
CD25 (IL2Rα) CXCR6, 
TNFSF4, TNFSF7, 
ITGA2 (CD49B), ITGB7, 
VCAM-1
20
Activating
CD244 (2B4), CD8, CD16, 
CD27, CD226, NKG2C, 
NKG2D, NKp30, NKp44, 
NKp46
Others 
CCR7
Activating
CD2, CD7, CD57, CD62L, 
CD69, CD161, LFA-1
None- however NK cells 
expanded as part of LAK 
cell population
59
Inhibitory
KIR2DL3, LIR-1
Inhibitory
GL183 KIR2DL1, NKB1, 
NKG2A
Others
CXCR3
Others
CCR5, CXCR4
19 ActivatingNKG2D, NKp44
Inhibitory
KIR2DL1 (in NK subsets 
expressing this single 
KIR)
Activating
NKp30, NKp46, 
(DNAM-)1 NK-cell depleted PBMC 
fraction- irradiated, 
autologous
65
Inhibitory
NKG2A, overall KIR 
subset composition
13
Activating 
NKG2D
NK-cell depleted PBMC 
fraction (containing T 
and B cells) = irradiated, 
autologous
78
Inhibitory
KIR2DL1, KIR2DL2
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strategy. For this protocol, the NK cells were magl
netically isolated in a 2lstep procedure, involving 
CD3ldepletion followed by CD56lselection, using 
the CliniMACS system (Miltenyi Biotec). Purified 
NK cells were then longlterm ILl2 stimulated and 
expanded in colculture with the GMPlcertified 
EpsteinlBarr virusltransformed Blcell line EBVl
TMlLCL (after irradiation) as feeder.53 The supl
portive medium was XlVIVO 20. Clinicallgrade NK 
cells expanded under such conditions 490l± 260lfold 
within 21 days. A comparison with NK cell growth 
in flasks showed similar NK cell yields for this protol
col. A comparison with fresh NK cells demonstrated 
a significant increase of cytolytic potential of such 
expanded NK effectors. Furthermore, 16 hours prel
treatment of renal cell carcinoma (RCC) cell lines (esl
tablished by the authors) with bortezomib sensitized 
them to lysis by such expanded NK cells (12l18 days) 
dramatically, whereas resting NK cell lysis was not 
significantly further enhanced. The group had previl
ously demonstrated that preltreatment (18lhrs) with 
bortezomib (10 nmol/L) sensitized 11 out of 13 RCC 
cell lines and 16 out of 37 other cell lines established 
from different cancer types, including leukemia, melal
noma, and solid tumors to allogeneic NK cell lysis.67 
The authors also found that viability of the longlterm 
expanded NK cells was not compromised under such 
conditions. These important data show promise for a 
combination therapy involving bortezomib and longl
term stimulated NK cells. It would be of great interl
est to investigate whether NK cells expanded in alterl
native culture protocols, e.g. without involvement of 
feeder cells, would be similarly responsive. 
In this paper the issue of sudden cytokine withl
drawal in a transplant setting and the issue of cryol
preservation of longlterm expanded NK cells were 
also addressed. ILl2 withdrawal for 16l24 hours and 
cryopreservation resulted in diminished cytotoxicity 
of the cells. It was suggested to include an additional 
ILl2lculture step after thawing in a clinical setting to 
restore effector function.53
Other promising new developments include inl
volvement of novel cytokines, such as ILl15, ILl6, or 
ILl21 or combinations of such76l78 or expansion of 
NK cells from umbilical cord blood as an alternative 
source.42,79l81 Protocols using cord blood as starting 
material,81 however, are still more complex and involve 
more components, e.g. number of stimulating factors 
compared to protocols reviewed above. A recent rel
view highlighted the benefits and challenges for use 
of umbilical cord blood compared to peripheral blood 
NK cells.82
General considerations for GMPtcompatible 
largetscale NK cell generation
Largelscale production of NK cells in longlterm ex vivo 
cultures poses new challenges compared to traditional 
and recent protocols involving fresh or shortlterm stiml
ulated NK cells.20 The costs for such procedures may 
be substantially increased and the risks of contaminal
tion high. As such, longlterm culture protocols require 
processing of the product inside facilities compliant 
with current GMPlregulations involving handling of the 
product by specially trained personnel.10,14 Strict release 
criteria and related testing, such as sterility, presence of 
mycoplasma species and levels of endotoxin, to control 
safety of the product are imperative. This may pose chall
lenges for fresh product administrations to patients, 
since test results would generally not be available directl
ly, thereby creating lag phases. Institutions need to del
termine the most informative time points for such tests 
to be taken, perhaps at several stages throughout culture 
duration. This feature imposes additional costs on the 
production. Frozen storage of the product and scheduled 
application at later points would allow overcoming such 
matters. Furthermore it would help in overcoming the 
observed expansion variability that does not only occur 
between donors, but also for cells isolated from the same 
donor at different time points.57 However, unfortunately 
cryopreservation may also lead to diminished NK cell 
potency53 and new strategies are needed to potentially 
overcome this potential drawback. Similarly, the effects 
of cytokine withdrawal and potential for adjuvant adl
ministration of (novel) cytokines should be explored in 
further detail to improve this type of therapy.
Some of the new translational protocols involve all
logeneic feeder cell sources to boost NK cell expansion. 
However, effects of continues triggering of NK cell rel
ceptors through ligands expressed by feeder cells are 
undefined. It may have beneficial or adverse effects on 
the NK cell product for clinical application, which rel
quires further investigation.37
Other relevant procedures of longlterm culture prol
tocols include monitoring of the cell phenotype, of cell 
densities and cell growth, and viability assessment of 
the product throughout the culture period. Dramatic 
phenotypic changes of the NK cell product after longl
term cytokine stimulation for receptor expression were 
identified by some authors (Table 1). The functional 
impact of changes in the receptor expression pattern 
is not fully understood. However, there is strong evil
dence that longlterm cytokine stimulation may be a 
potential means for overcoming inhibitory signaling 
through upregulation of major activating receptors, 
such as NKG2D78,83,84 (Table 1). Of great value would 
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